Alkermes (ALKS) Long-Term Investments (2011 - 2026)
Alkermes (ALKS) posted quarterly Long-Term Investments of $35.1 million for Q2 2026, down 8.4% year-over-year from $38.3 million in Q2 2025, and up 32.97% quarter-over-quarter from $26.4 million in Q1 2026.
Alkermes (ALKS) Long-Term Investments (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Long-Term Investments for 16 consecutive years, with $35.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Long-Term Investments fell 8.4% year-over-year to $35.1 million; the TTM figure through Jun 2026 stood at $35.1 million (down 8.4% YoY), while the FY2025 annual figure was $145000.0, down 99.8% from the prior year.
- Long-Term Investments advanced to $35.1 million in Q2 2026 per ALKS's latest filing, from $26.4 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $229.8 million in Q1 2022 and bottomed at $145000.0 in Q4 2025.
- Historically, Long-Term Investments has averaged $79.2 million across 5 years, with a median of $68.0 million in 2024.
- Annual changes were most pronounced in 2022 — Long-Term Investments soared 165.85% — and 2025, when it slumped 99.8%.
- Alkermes' Long-Term Investments stood at $131.6 million in 2022, then slumped by 69.69% to $39.9 million in 2023, then surged by 83.39% to $73.1 million in 2024, then plunged by 99.8% to $145000.0 in 2025, then surged by 24075.17% to $35.1 million in 2026.
- Business Quant data shows ALKS's Long-Term Investments at $35.1 million in Q2 2026, $26.4 million in Q1 2026, and $145000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | 92.58 Mn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 63.23 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 1.14 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 60.00 Mn |
| 10 | Alkermes | 8.07 Bn | 7.42 Bn | 397.90 Mn | 35.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.05 Mn |
| Mar 31, 2026 | 26.36 Mn |
| Dec 31, 2025 | 145,000.00 |
| Sep 30, 2025 | 27.87 Mn |
| Jun 30, 2025 | 38.27 Mn |
| Mar 31, 2025 | 32.19 Mn |
| Dec 31, 2024 | 73.15 Mn |
| Sep 30, 2024 | 18.92 Mn |
| Jun 30, 2024 | 86.40 Mn |
| Mar 31, 2024 | 62.78 Mn |
| Dec 31, 2023 | 39.89 Mn |
| Sep 30, 2023 | 106.43 Mn |
| Jun 30, 2023 | 78.13 Mn |
| Mar 31, 2023 | 92.08 Mn |
| Dec 31, 2022 | 131.61 Mn |
| Sep 30, 2022 | 166.93 Mn |
| Jun 30, 2022 | 179.01 Mn |
| Mar 31, 2022 | 229.83 Mn |
| Dec 31, 2021 | 229.43 Mn |
| Sep 30, 2021 | 187.86 Mn |